FARNESYLTHIOSALICYLIC ACID
Salirasib
CAS: 162520-00-5
Molecular Formula: C22H30O2S
FARNESYLTHIOSALICYLIC ACID - Names and Identifiers
FARNESYLTHIOSALICYLIC ACID - Physico-chemical Properties
| Molecular Formula | C22H30O2S |
| Molar Mass | 358.54 |
| Density | 1.05 |
| Melting Point | 64-66°C |
| Boling Point | 486.0±45.0 °C(Predicted) |
| Solubility | DMSO <20mg/mL; Ethanol <20mg/mL; DMF <20mg/mL |
| Appearance | powder |
| Color | white to beige |
| pKa | 3.50±0.36(Predicted) |
| Storage Condition | -20°C |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| In vitro study | Salirasib inhibits the growth of human Ha-ras-transformed Rat1 cells, which correlates well with their inhibition for PPMTase. Salirasib inhibits Ras methylation in Rat-1 fibroblasts, Ras-transformed Rat-1, and B16 melanoma cells. Salirasib also reduces the levels of Ras in cell membranes and inhibits Ras-dependent cell growth, independently of methylation but via modulation of Ras-Raf communication. In Ras-transformed EJ cells, Salirasib interactions with the activation of Raf-1 and MAPK and inhibitors DNA synthesis. Salirasib inhibits the growth of human transformed Rat1 cells by Ha-ras, which correlates well with their inhibition of PPMTase. Salirasib inhibits Ras methylation in Rat-1 fibroblasts, Ras-transformed Rat-1, and B16 melanoma cells. Salirasib also reduces Ras levels in cell membranes and inhibits Ras-dependent cell growth, which is independent of methylation but regulated by Ras-Raf communication. In Ras-transformed EJ cells, Salirasib interferes with Raf-1 and MAPK activation and inhibits DNA synthesis. |
| In vivo study | In Panc-1 xenografted nude mice, Salirasib (5 mg/kg I. p.) markedly inhibits tumor growth without systemic toxicity. In male Wistar rats, Salirasib (5 mg/kg I. p.) marked indications thioacetamide-induced -induced liver circulation. In the dy(2J)/dy(2J) mouse model of pulmonary muscular dystrophy, Salirasib (5 mg/kg I. p.) attenuates fibrosis and improvements muscle strength. In Panc-1 xenografted nude mice, Salirasib (5 mg/kg I. p.) significantly inhibited tumor growth without systemic toxicity. In male Wistar rats, Salirasib (5 mg/kg I. p.) significantly inhibited thioacetamide-induced cirrhosis. In the dy(2J)/dy(2J) mouse model of congenital muscular dystrophy, Salirasib (5 mg/kg I. p.) attenuates fibrosis and increases muscle strength. |
FARNESYLTHIOSALICYLIC ACID - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.789 ml | 13.945 ml | 27.891 ml |
| 5 mM | 0.558 ml | 2.789 ml | 5.578 ml |
| 10 mM | 0.279 ml | 1.395 ml | 2.789 ml |
| 5 mM | 0.056 ml | 0.279 ml | 0.558 ml |
Last Update：2024-01-02 23:10:35
Supplier List
Spot supply
Product Name: Salirasib Visit Supplier Webpage Request for quotationCAS: 162520-00-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Salirasib Visit Supplier Webpage Request for quotationCAS: 162520-00-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History